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THE TREATMENT OF 
PARKINSON’S DISEASE USING NOVEL MAO-B INHIBITORS 
AUSTIN JOSEPH PARSONS 
 
ABSTRACT 
 Monoamine Oxidase Inhibitors have sparked great controversy in the 
treatment of idiopathic Parkinson’s Disease. There is little doubt that Monoamine 
Oxidase Inhibitors work synergistically with Levodopa to reduce several major 
debilitating symptoms. Multiple other medications provide a similar symptomatic 
benefit when combined with Levodopa; thus, a symptomatic benefit alone does 
little to advance current Parkinson’s treatment. The great controversy in treatment 
then comes from the possibility that Monoamine Oxidase Inhibitors modify the 
natural course of Parkinson’s Disease. This class of drug protected nigrostriatal 
dopaminergic neurons in many cellular and animal studies. Clinical studies 
involving Monoamine Oxidase Inhibitors are more controversial. Several studies 
have shown results that suggest a neuroprotective effect while other have not. This 
may be because the tools used to assess PD progression are inadequate. To see 
a clear decrease in nigrostriatal dopaminergic death, and thus prove a 
neuroprotective effect, more advanced techniques to measure the progression of 
Parkinson’s Disease must be developed. Given the controversy it will be important 
to revisit the benefits of MAO-B inhibitors once more advanced progression 
techniques are available.   
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INTRODUCTION 
Parkinson’s Disease (PD) is a chronic and progressive neurodegenerative disease 
which destroys neurons in the Substantia Nigra Pars Compacta (SNPC), a 
subnuclei of the Basal Ganglia. This degeneration causes the 4 cardinal signs of 
PD: tremor, bradykinesia, rigidity, and postural instability. In addition to these 
debilitating physical costs there are also incredible financial costs. In the United 
States alone the combined direct and indirect cost of patient care is nearly 25 billion 
dollars a year. Medication costs a patient on average around $2,500 yearly, and a 
surgery to alleviate symptoms can cost up to $100,000.  As with many 
neurodegenerative diseases the incidence of PD increases dramatically with age, 
only an estimated 4% of those diagnosed with PD are under the age of fifty. Each 
year approximately sixty thousand people are diagnosed with PD in the United 
States alone. In the United States around one million people live with PD, more 
than those living with Multiple Sclerosis, Muscular Dystrophy, and Lou Gehrig’s 
Disease combined (“Parkinson’s Disease Foundation (PDF) - Hope through 
Research, Education and Advocacy,” n.d.).  
A). Anatomy & Physiology of PD 
1). Anatomy of The Basal Ganglia 
 The basal ganglia are a group of subcortical nuclei which help to regulate 
motor control, motor learning, and behavior (Lanciego, Luquin, & Obeso, 2012). 
The basal ganglia refer to the Striatum, Globus Pallidus (GP), and several 
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subnuclei located deep in the brain’s hemispheres. The basal ganglia’s subnuclei 
include the Subthalamic nucleus (STN), located within the diencephalon, the 
Substantia Nigra (SN), located within the mesencephalon, and the 
Pedunculopontine Nucleus, located within the pons (Lanciego et al., 2012). The 
Striatum lies directly deep to the cortex, and is separated into the Caudate Nucleus 
and the Putamen by a white matter tract known as the Internal Capsule. The two 
components of the Substantia Nigra, the Substantia Nigra Pars Compacta (SNPC) 
and the Substantia Nigra Pars Reticulata (SNPR), are located inferior to the 
Thalamus and are deep and medial to the Globus Pallidus. The Globus Pallidus 
externus (GPe) and internus (GPi) are located deep and medial to the Putamen 
and inferior to the Caudate (Figures 1 and 2).   
 
Figure 1: Coronal View of the Basal Ganglia Structures: 
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This figure illustrates many of the important structures of the Basal Ganglia and 
their anatomical location to one another. The Caudate and the Putamen make up 
the Neostriatum or simply the Striatum. Medial to the putamen is the Globus 
Pallidus, which has both and external and internal components. In this figure, the 
anatomical proximity of the Substantia Nigra and the Subthalamic Nucleus to both 
the GP, and therefore the Thalamus is clear.  
Source: (University of Wisconsin, n.d.) 
 
Figure 2: Parasagittal view of the Basal Ganglia: 
Source: (Lanciego et al., 2012) 
 
2). Basal Ganglia Physiology  
The SNPC forms dopaminergic connections to the Striatum (Moore, 2005). These 
are the dopaminergic neurons which die in PD, which is why PD is typically 
classified by the loss of nigrostriatal DA.   
 
There are several models for the circuitry of the Basal Ganglia. The “Standard 
Model” is useful to explain many observations regarding basal ganglia function 
(Figure 3). Per the Standard Model, axons from the SNPC release DA into the 
Striatum which activates both D1 and D2 receptors. The D1 receptors activate the 
“Direct Pathway”. This pathway is responsible for turning on the Thalamus, leading 
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to increased motor output. Activating the D2 receptors inhibits the “Indirect 
Pathway”. The Indirect Pathway is responsible for turning off the Thalamus, and 
thus decreasing motor output. In a Parkinsonian state without DA in the Striatum, 
neither D1 or D2 receptors are stimulated. This leaves the Indirect Pathway 
unopposed. The Indirect Pathway keeps the Thalamus turned off, leading to 
decreased movement.  
 
FIGURE 3: Standard Model of Basal Ganglia Circuitry: 
Activating the D1 pathway will inhibit the GPi/SNr. This inhibition prevents the 
release of inhibitory gamma-Aminobutyric acid (GABA) onto the Thalamus. The 
now uninhibited Thalamus will release excitatory Glutamate onto the cortex which 
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will allow for motion. Activating the D2 receptors causes inhibition of the GPe, 
which allows the STN to be activated. The activated STN releases Glutamate onto 
the GPi/SNr which activates them and they in turn inhibit the Thalamus.   
(Ellens & Leventhal, 2013) 
B). Pathology of Parkinson’s Disease 
Parkinson’s Disease is characterized by the presence of Lewy Bodies (LB). Lewy 
Bodies in the SN are eosinophilic inclusions in the cytoplasm of neurons. They 
have a dense core and typically have a “halo” of fibrils which radiate outwards. 
Alpha-Synuclein (α-Synuclein) is the main protein in LB’s; however ubiquitin, 
neurofilament protein, and Tau protein may also be present (Engelender, 2008) 
(Ishizawa, Mattila, Davies, Wang, & Dickson, 2003) (Arima et al., 1999). Lewy 
Neurites (LN) are also common in PD pathology. Lewy Neurites have not formed 
a full LB in their cytoplasm, but are abnormal neurons containing excessive 
amounts of α-synuclein. (Spillantini, Crowther, Jakes, Hasegawa, & Goedert, 
1998). Lewy bodies and Lewy Neurites have often been pointed to as the cause 
of PD by affecting the microtubule based transport system (Sheng & Cai, 2012); 
however, there are many theories that suggest these builds ups are a byproduct 
not a cause (Rhodes et al., 2014) 
1). Oxidative Stress Model of Parkinson’s Disease 
A major theory on how PD develops states that oxidative stress build up in the 
SNPC causes death of these neurons. Oxidative stress is implicitly linked to cellular 
death pathways and has been shown to lead to apoptosis (Kannan & Jain, 2000). 
Neurons rely heavily on aerobic respiration for their ATP. Byproducts of oxidative 
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phosphorylation are hydrogen peroxide and superoxide radicals, which are both 
known to contribute to oxidative stress. The dopaminergic SNPC neurons are 
particularly susceptible to oxidative stress due to the presence of Tyrosine 
Hydroxylase (TH) and Monoamine Oxidase (MAO) which are known to generate 
reactive oxygen species (ROS) (Hwang, 2013). Nigral DA neurons also contain 
iron which catalyzes the Fenton reaction. This can also provide additional oxidative 
stress (Halliwell, 1992).  DA itself has also been implicated in causing oxidative 
stress. Excess DA is oxidized both spontaneously and by enzymes to produce DA 
Quinone (Hwang, 2013). This DA Quinone covalently modifies α-synuclein into the 
cytotoxic form (Conway, Rochet, Bieganski, & Lansbury, 2001). The SNPC of PD 
patients exhibits a dramatic increase in oxidized lipids (Bosco et al., 2006) and 
nucleic acids (Nakabeppu, Tsuchimoto, Yamaguchi, & Sakumi, 2007).  These 
studies provide strong evidence that the Nigral DA neurons are subject to high 
levels of ROS species leading to extreme oxidative stress.  
2). Progression of Parkinson’s Disease 
Monitoring the progression of PD in a patient is very difficult for clinicians. Even 
advanced imaging techniques are inadequate to measure the exact amount of 
nigral loss. Clinicians most commonly rely on the Unified Parkinson’s Disease 
Rating Scale (UPDRS) (Appendix 1), which is a more detailed extension of the 
brief Hoehn and Yahr staging. Part I of the UPDRS assesses behavioral problems. 
Part II assesses patients’ perceptions of their ability to carry out activities of daily 
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living. Part III, the clinician’s exam, covers the motor evaluation of disability, and 
includes ratings for tremor, bradykinesia, rigidity, and balance. Part IV covers 
several treatment complications, including ratings of dyskinesia, dystonia, and 
irregular medication responses (“New Scale for Measuring PD Increases Role of 
Patients and Caregivers - Parkinson’s Disease Foundation (PDF),” n.d.).  
 
The UPDRS has consistently been identified as the best available tool to measure 
the stage and progression of PD. The UPDRS has several weaknesses however. 
The most notable weakness of the UPDRS is the ambiguity between various 
answers choices which are marked by the clinician. This leads the scale to be 
subject to high subjectivity. The UPDRS places a large emphasis on severe 
impairments, which does not allow the scale to detect subtle changes in 
parkinsonian symptoms. A final flaw in the UPDRS is that it does not include 
several non-motor symptoms including depression, anxiety, and apathy 
(Gallagher, Goetz, Stebbins, Lees, & Schrag, 2012). Clinicians now categorize 
these as parkinsonian, and thus the UPDRS is incomplete.  
 
To attempt to remedy these problems the Movement Disorder Society (MDS) 
sponsored the creation of a new scale: the MDS-Sponsored UPDRS Revision 
(MDS-UPDRS) (Goetz et al., 2007).  Several of the key differences in the new 
MDS-UPDRS include directly asking the patient and their caregivers questions, 
adding descriptive language to each of the numerical scores to help reduce 
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subjectivity, and increasing the emphasis on mild impairment. The MDS-UPDRS 
should allow researchers to detect more subtle changes in symptoms. This is 
increasingly important when talking about potential neuroprotective effects of PD 
treatments (Goetz et al., 2007).  
C). Animal Models of Parkinson’s Disease 
Animal models serve an important role in PD research, as in general medical 
research. Various methods are used to attempt to “induce” the onset of PD into 
otherwise healthy neural models. Two of the more successful methods come from 
a toxic injection of either 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 
6-hydroxydopamine (6-OHDA).  
1).Treatment with MPTP 
MPTP treatment has been shown to mimic PD in humans (Davis et al., 1979). 
MPTP is able to seemingly reproduce PD symptoms in primates and certain mouse 
strains by a simple injection. Lower species are not as sensitive to MPTP. This 
could be due to their rapid clearance of 1-methyl-4-phenylpyridinium (MPP+), a 
metabolite of MPTP which seems to be the cause of the onset of parkinson like 
symptoms (Herkenham et al., 1991). MPTP’s mechanism of action is well 
understood (Figure 4). MPTP is taken up by glial cells which convert MPTP into 
MPP+ via Monoamine Oxidase.  MPP+ is released from glial cells and is quickly 
taken up by the dopamine transporter (DAT). Once inside the neuron MPP+ inhibits 
mitochondrial respiration by impairing the function of complex I of the electron 
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transport chain (Nicklas, Youngster, Kindt, & Heikkila, 1987). This leads to a 
decrease in ATP production, the formation of ROS, and ultimately the depletion of 
the dopaminergic neurons in the SNPC. 
 
FIGURE 4: Molecular Mechanism of MPTP & 6-OHDA 
The “*” next to 6-OHDA indicates that the substance has been directly injected into 
the brain. Figure 4 shows the various agents that may lead to nigro-striatal tract 
degeneration. 
(Duty & Jenner, 2011) 
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2). Treatment with 6-OHDA 
6-OHDA, or 6-hydroxydopamine, is DA with oxygen attached at the sixth position. 
6-OHDA cannot cross the blood brain barrier so it must be directly injected into the 
brain. Figure 4 above shows the general mechanism of 6-OHDA. Researchers are 
unsure of 6-OHDA’s direct mechanism, but it is known that both complex I and IV 
are directly disrupted (Glinka, Gassen, & Youdim, 1997). 6-OHDA treatment 
ultimately leads to dopaminergic cell death and SNPC lesions, which show 
physiologic similarity to PD (Figure 4).  
3). Construct Validity of Toxin Induced PD 
Toxin induced models have had success in replicating many features of PD, thus 
increasing their construct validity. 6-OHDA treatment activates microglial cells 
through the PK11195 ligand (Cicchetti et al., 2002). This same ligand is a common 
marker of neuroinflammation in PD patients, and 6-OHDA treatment activates 
PK1195 in a very similar pattern as PD (Gerhard et al., 2006). No study has been 
done to examine whether MPTP directly activates the microglia in the same way 
that PD and 6-OHDA do. It is known, however, that MPTP creates mircogliosis 
(Hébert, Arsaut, Dantzer, & Demotes-Mainard, 2003) (Kurkowska-Jastrzebska, 
Wrońska, Kohutnicka, Członkowski, & Członkowska, 1999).  
Treatment with 6-OHDA or MPTP leads to many of the biochemical hallmarks of 
PD including depleted striatal DA and reduced TH levels (Duty & Jenner, 2011).  
The MPTP model shows additional similarities to the actually PD state. These 
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include an increase in Striatal acetylcholine (Hadjiconstantinou, Cavalla, 
Anthoupoulou, Laird, & Neff, 1985), an increase in extracellular glutamate which is 
consisent with programmed cell death (Meredith, Totterdell, Beales, & Meshul, 
2009), and an appropriate decrease in gluathione levels (Ferraro, Golden, 
DeMattei, Hare, & Fariello, 1986).  
 
One major downfall of both of these toxin models is that neither has convincingly 
shown the presence of any LB inclusions. Interestingly, early studies involving 
MPTP showed the gradual onset of these LB inclusions, although they were 
slightly different than the typical PD LB’s (Meredith et al., 2002). Later studies 
involving MPTP have not been able to replicate these inclusions using the same 
treamtent regiment, casting doubt on their exsistence (Fornai et al., 2005) (Shimoji, 
Zhang, Mandir, Dawson, & Dawson, 2005). 
 
 In addition to the lack of a LB presence in these toxin models it is also important 
to note that both of these toxins produce a rapid cell death, which is the opposite 
of PD progression. PD onset in a normal patient will take decades of 
neurodegeneration  before a symptomatic state is reached. A final point to mention 
regarding MPTP is that occasionally it exhibits a phenomenon where initially 
catecholamines are depleted, but then, over the course of the following 2 months 
and independent of any intervention, the catecholamine levels begin to rise 
(Hallman, Lange, Olson, Strömberg, & Jonsson, 1985). This point is important due 
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to the fact several studies attempt to measure Striatal DA levels directly after 
MPTP injection, and then again post-intervention. Hallman’s study sugguests that 
the results of those studies should be critically evalutated. 
 
 All in all these toxin induced models of PD have high construct validity despite the 
rapid acceleration of PD in nigro striatal neurons. Even though these models do 
not show LB pathology they are able to mimic the biochemical hallmarks of PD in 
a way few other interventions are able to.  
 
D). Other Treatments for Parksinson’s Disease     
There are several major types of medications currently available to treat PD. All of 
these medications only provide symptomatic relief for a fleeting period of time. No 
medications are currently available which the medical community unanimously 
agrees slows, yet alone stops, the progression of the parkinsonian pathology. A 
more comprehensive list of PD medications can be found under Appendix 2.  
 
The most basic treatment for PD is the DA agonist. The logic for this class of 
medication is to simply bind to the DA receptors in the Striatum, essentially 
attempting to mimic the normal physiologic effects of DA. DA agonists are linked 
to many undesireable side effects. Notable symptoms include severe somnolence, 
perhiperal edema, and complusive behaviors (Wood, 2010).  
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Levodopa (L-Dopa), brand name Sinement, is the most common treatment for PD, 
and the most effective at reducing the symptoms of PD. Levodopa is used instead 
of directly using DA mainly because DA is not able to cross the Blood Brain Barrier 
(BBB), and it causes patients to vomit. Levodopa is given in combination with 
Carbidopa in order to prevent peripheral decarboxylation (conversion into DA) 
which leads to nausea and orthostatic hypotension. Levodopa is then free to cross 
the blood brain barrier where it is converted into DA by DOPA decarboxylase, while 
Carbidopa is left behind. L-Dopa increases the amount of Striatal DA, which 
improves symptoms in patients. L-dopa reduces almost all motor symptoms of PD 
during the first 6 months of use, which is refered to as the “honeymoon period”. At 
this stage L-dopa rarely wears off in effectiveness between doses, and thus 
patients are afforded protection from their motor symptoms nearly full time. After 
this honeymoon period wears off patients expereince increases in daily “off time”, 
which refers to time between doses where the effect of L-dopa has worn off and 
their symptoms return. Levodopa, despite showing pronounced effects in reducing 
parkinsonian symptoms, has also been shown in several studies and in general 
clinical practice to actually create new dyskiesias termed Levodopa Induced 
Dyskinesias (LIDs); however these are usually minimal when compared to the 
benefits of L-Dopa (Thanvi, Lo, & Robinson, 2007). Many PD treatments center 
around increasing the amount of daily “on time” for patients to ensure a masking 
in symptoms for the longest duration possible.  
 
 14 
 
Catechol O-Methyl Transferase Inhibitors (COMT Inhibitors) act in the periphery to 
decrease the amount of DA that is degraded. COMT specifically works to 
metabolize DA and other catecholamines, so its inhibition should allow for more 
DA to reach the Striatum. COMT inhibitors are only approved to be used as an 
adjunct therapy to L-Dopa, not as a monotherapy.  
 
Anticholinergic medications, which are antimuscarinics, are sometimes used as a 
medication for tremor. However, they have severe side effects including cognitive 
decline (Ehrt, Broich, Larsen, Ballard, & Aarsland, 2010) and urinary retention 
(Lertxundi et al., 2015). These effects are particularly troublesome in elderly patient 
populations, and as such anitcholinergic medications are rarely used in the 
treatment of PD.  
 
Amantidine is an antiviral medication which has antiparkinsonian properties. 
Removing Amantidine from a patient’s medication regiment has been shown to 
increase dyskinesia (Ory-Magne et al., 2014). Amanditine has been shown to help 
reduce the lack of impluse control many PD patients show (Thomas, Bonanni, 
Gambi, Di Iorio, & Onofrj, 2010). Amantidine has a plethora of mild side effects, 
but most PD patients tolerate Amantidine well.  
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FIGURE 5: Location of Treatment Interventions in Parkinson’s Disease 
Source:(“The Clinicians’ and Nurses’ Guide to Parkinson’s Disease,” n.d.). 
 
E). Overview of Monoamine Oxidase Inhibitors 
Monoamine Oxidase (MAO) is a flavoprotein located in the mitochondrial outer 
membrane, which breaks down monoamine neurotransmitters such as dopamine, 
norepinephrine, and serotonin, and other non-neurotransmitter amines. MAO’s act 
as scavengers of other amines like tyramine and tryptamine. Finally, the MAO 
flavoprotein is responsible for converting MPTP into MPP+, a parkinsonian agent 
(Wouters, 1998).   MAO inhibitors are used currently to treat atypical depression 
(“Atypical Depression in the 21st Century,” 2012), and Parkinson’s disease.  
 There are two isoforms of MAO enzymes: MAO-A and MAO-B. Very few tissues 
express exclusively isoform “A” or “B”, rather one isoform will be the majority in a 
given tissue (Wouters, 1998). MAO-A is utilized more to break down dietary 
vasopressors, serotonin, norepinephrine, and epinephrine. MAO-B is the primary 
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MAO isoform in the human brain found specifically in astrocytes and 
monoaminergic neurons, and it is used to break down dopamine and 
phenethylamine. 
1). Structure of MAO-B 
MAO-B utilizes an FAD cofactor to act as an oxidizing agent. This FAD is covalently 
bound to Cysteine 397 by a riboflavin linkage (Binda, Newton-Vinson, Hubálek, 
Edmondson, & Mattevi, 2002). The active site of the MAO-B enzyme is located 
directly underneath the location that FAD is covalently bound. Substrates enter 
into the MAO-B enzyme through an entrance cavity located directly adjacent to the 
active site and loop 99-112 (Figure 6) (Binda et al., 2002).  
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FIGURE 6: Active site structure of MAO-B:  
The top image shows that MAO-B exists as a dimer. The figure also shows the 
transmembrane domain of MAO-B, which is anchored to the outer mitochondrial 
membrane. In the bottom image FAD is a ball and stick model in yellow. Directly 
underneath FAD is the active site of MAO-B, which is in cyan. The entrance cavity 
is in purple directly next to loop 99-112 and the active site. The transmembrane 
domain is represented in green.  
(Binda et al., 2002) 
2). Mechanism of Action 
The following figures detail the mechanism by which MAO-B breaks down its 
substrate. Both figures show that the main feature of the MAO-B enzyme is its FAD 
cofactor, which is the oxidizing agent of the MAO-B catalyzed reaction. 
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Figure 7: General Mechanism of MAO’s: 
MAO’s couple the oxidation of the substrate with reduction of an FAD cofactor. The 
product is the corresponding imine of the substrate, which spontaneously 
hydrolyses into an aldehyde and ammonia. FAD is then re-oxidized which yields a 
hydrogen peroxide molecule.  
(Wouters, 1998). 
 
 
 
 
FIGURE 8: Oxidation /Reduction Mechanism of MAO-B: 
This mechanism’s detail shows the true importance of FAD. Without FAD MAO-B 
would not be able to perform any step of the reaction.  
(Binda et al., 2002) 
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3). MAO-B Inhibition 
Inhibitors have difficulty reaching the active site of MAO-B. MAO-B inhibitors are 
therefore designed to interact with a more accessible site. MAO-B inhibitors attach 
to the N5 atom of the FAD cofactor and prevent its proper utilization. By not 
allowing the FAD cofactor to be utilized effectively they suppress the activity of the 
MAO-B flavoprotein.  
 
 
FIGURE 9: Binding Pocket of MAO-B Inhibitors:  
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The gray pouch is the binding pocket for MAO-B inhibitors. The figure showcases 
the common structure of these inhibitors and demonstrates their key covalent bond 
to the N5 atom. The Flavin is shown above the inhibitor with numbered atoms. The 
binding pocket is formed by many aromatic and aliphatic amino acids, which 
provide the highly hydrophobic environment needed by these inhibitors. Residues 
which are the same in MAO-A are marked with asterisks.  
(Binda et al., 2002) 
4). Safety Concerns Using MAO-B Inhibitors 
Figure 9 shows that two thirds of the binding pocket residues are the same in both 
MAO isoforms. This led to the belief that designed inhibition of either MAO-A or 
MAO-B would lead to partial inhibition of the other as well. This brought up many 
safety concerns especially concering tyramine, which is found in many foods 
including old cheeses. When excess tyramine is consumed while taking a MAO 
inhibitor, the MAO enzyme is using its limited functional ability to breakdown the 
tyramine. This causes a build up in norepinphrine and epinephrine, causing a 
hypertensive crises similar to those seen in a pheochromocytoma 
(Sathyanarayana Rao & Yeragani, 2009). This hypertensive crisis can also be 
caused by various over-the-counter medications namely decongestants and 
antitussives. These medications include, but are not limited to: ephedrine, 
pseudoephedrine, dextroamphetamine, and reserpine. The hypertensive crisis 
that is possible with MAO inhibition highlights the reason why very selective MAO 
inhibitors needed to be produced. For the treatment of PD, MAO-B must be 
selectively inhibited. MAO-A must remain mostly uninhibited in order to mitigate 
the possibility of a patient experiencing a potentially life-threatening hypertensive 
crisis.  
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F). OVERVIEW OF SPECIFIC MONOAMINE OXIDASE INHIBITORS 
1). Selegiline 
In the late 1960’s Joseph Knoll developed what was known as Selegiline or (-)-
Deprenyl. This was the first drug that could selectively inhibit the B isoform of MAO 
enzymes (Knoll & Magyar, 1972), and was the first MAO-B inhibitor approved for 
the treatment of PD.  
 
FIGURE 10: Structure of Selegiline 
(DrugBank, 2017b).  
a). Metabolism 
 In Selegiline’s first pass it undergoes extensive processing in the liver where it is 
converted into L-methamphetamine and Desmethylselegiline by select 
cytochrome p450’s. These metabolites can undergo further processing and yield 
L-amphetamine (Figure 11).  
 22 
 
 
Figure 11: Selegiline breakdown into Amphetamine metabolites:  
(Chen, Swope, & Dashtipour, 2007) 
 
Selegiline’s metabolites L-methylamphetamine and L-amphetamine have been 
shown to substantially decrease striatal DA and TH levels (Bowyer et al., 1998) 
(Preston, Wagner, Schuster, & Seiden, 1985). This finding prompted questioning 
about Selegiline’s efficacy for PD, and thus initiated the development of an MAO-
B inhibitor without these metabolites.  
2). Rasagiline 
Rasagiline is a second-generation MAO-B inhibitor approved by the US food and 
drug administration under the brand name Azilect. Rasagiline is approved as both 
a monotherapy and adjunct therapy for early to late stage PD.  
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FIGURE 12: Structure of Rasagiline.  
(DrugBank, 2017a).  
  
a). Metabolism 
Like Selegiline, Rasagiline undergoes extensive hepatic processing by a specific 
cytochrome p450. This leads to the formation of Aminoidan, a non-amphetamine 
metabolite, which is excreted. Rasagiline was lauded as a new promising MAO-B 
inhibitor due to its lack of amphetamine metabolites. Aminoidan may also weakly 
inhibit MAO-B as well (Bar-Am, Amit, & Youdim, 2007) (Tazik et al., 2009).  
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Figure 13: Biochemical Conversion of Rasagiline to Aminoidan. 
Reaction converting Rasagiline into Aminoidan by use of a Cytochrome P450 
enzyme. Aminoidan has also been reported to inhibit MAO-B. 
(Finberg, 2010) 
3). Safinamide 
Safinamide, brand name Xadago, is an MAO-B inhibitor, a sodium channel 
blocker, and also blocks the release of excessive glutamate (Fabbri, Rosa, Abreu, 
& Ferreira, 2015).  
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FIGURE 14: Chemical Structure of Safinamide.  
(Caccia et al., 2006) 
Safinamide is more selective for MAO-B versus MAO-A by 1,000 fold. Rasagiline 
is 103 time more effective at binding MAO-B versus the A isoform, and Selegiline, 
127 fold in favor of isoform B (Kulisevsky, 2015). Safinamide is a reversible 
inhibitor of MAO-B unlike Rasagiline and Selegiline, which are both irreversible 
inhibitors. This property allows Safinamide to be effective at blocking MAO-B 
without any preincubation as shown by their identical IC50 (Figure 15) (Caccia et 
al., 2006).  
 
FIGURE 15: Safinamide’s Reversibility on the MAO-B Substrate Allows for 
Inhibition without Preincubation.  
(Caccia et al., 2006).  
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a). Metabolism 
Safinamide is broken down through many metabolic pathways involving various 
enzymes, including MAO-A. Little is known about its full metabolic pathway 
however a hypothesized pathway is shown below in Figure 16.  
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FIGURE 16: Hypothesized Metabolism of Safinamide.  
None of the metabolites of Safinamide are known to cause health risks, or affect 
any potential neuroprotective effect.  
(Leuratti et al., 2013). 
 
  
 
 
G). Specific Aims  
The specific aims of this thesis include:  
1. Review the basic research which supports claims that MAO-B inhibitors 
provide neuroprotection to dopaminergic neurons in the nigrostriatal 
pathway.  
2. Provide a comprehensive review of the clinical trials involving MAO-B 
 inhibitors.  
3. Conclusion on the validity of MAO-B inhibitors as a neuroprotectant in 
Parkinson’s Disease patients.  
 
MAO-B INHIBITORS ROLE IN NEUROPROTECTION 
MAO-B inhibitors were first theorized to help treat PD because inhibition of MAO-
B would lead to more available nigrostriatal DA, which would help to alleviate PD 
symptoms. MAO-B inhibitors gained rapid traction as a potential cure for PD 
because of the numerous in-vitro and animal studies showing evidence of 
neuroprotection. Many of these studies show that the created pathogenesis had 
been completly halted. Three major types of these studies are studies done 
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examining biomarkers from cell cultures, studies done in vivo in mice, and studies 
which use images of live cell populations responding to the inhibition of MAO-B. 
 
A). Studies Examing Biomarkers from Cell Cultures 
A major factor leading to cell death is Ca++ dysregulation (Giorgi et al., 2012). MAO-
B in astrocytes causes improper Ca++ homeostasis, and induces apoptosis 
(Vaarmann, Gandhi, & Abramov, 2010). Wu and colleagues first showed that 
treatment of SH-SY5Y cells, a human derived cell line expressing dopaminergic 
markers, with PK11195, an isoquinoline carboxamide, greatly increased their 
cytoplasmic Ca++ levels. They next showed that these high levels of Ca++ caused 
cell death. Wu et.al. used this cell line to show that Rasagiline and Selegiline do 
not allow the Ca++ increase required to cause mitochondrial induced apoptosis 
(Figure 17) (Wu, Kazumura, Maruyama, Osawa, & Naoi, 2015).  
 
Wu’s interventions involved pre-treating the cells with Rasagiline or Selegiline and 
then treating with PK11195. Both Rasagiline and Selegiline impressively lowered 
the Ca++ influx, and drastically reduced the percentage of dead cells.  The study 
suggests that both Rasagiline and Selegiline are neuroprotective by helping to 
conserve dopaminergic neurons in the striatum.  This study relies on pre-treatment 
with MAO-B inhibitors. Pre-treatment with MAO-B inhibitors is not a feasible 
intervention in human populations. However, since PD is a progressive disease, 
although the initial damage will remain, in theory once treatment with an MAO-B 
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inhibitor begins additional damage caused by apoptosis of the cells in the striatum 
should be greatly diminished.  
 
 
                                  
FIGURE 17: PK11195 Injection leads to a major Ca++ influx leading to cell 
death.  
In figures A&C on the left Wu et.al. show the incredible spike in Ca++ when SH-
SY5Y cells are treated with PK11195 versus the control untreated cells. On the 
right hand side figures A&B show that this Ca++ efflux is responsible for causing 
cellular death.   
(Wu et al., 2015) 
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Figure 18: Pre-Treatment with Rasagiline and Selegiline inhibits the Ca++ 
influx. 
Figure C&D on the left hand side show the effect of pre-treatment with Rasagiline 
on lowering the Ca++ efflux induced by PK11195. For each dose of PK11195 given 
Rasagiline pre-treatment lowers the Ca++ efflux by around 50%. Figures A&C on 
the right show pre-treatment with Selegiline lowering the Ca++ efflux induced by 
PK11195.  
(Wu et al., 2015) 
 
B). Studies done in Animal Models-stopped 
Some of the earliest studies which show MAO-B inhibitors may be 
neuroprotectants involved using MPTP injected mice. One such study involved 
pre-treating mice with several general MAO inhibitors, Selegiline, and an untreated 
control group. These mice were then injected with MPTP and their DA levels were 
examined. The researchers found that very little nigrostriatal DA was present in 
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the untreated group and the group treated with general MAO inhibitors when 
compared to the group treated with Selegiline.  
 
As previously stated using MPTP to study DA levels is difficult due to its effect on 
lowering DA levels initially, regardless of intervention. This study provides 
reasonable evidence that the interventions are what cause DA levels to be 
preserved, by using an untreated group and a group using a general MAO 
inhibitor.(Heikkila, Manzino, Cabbat, & Duvoisin, 1984). Both of these groups 
showed much lower DA, indicating that that result of the MAO-B specific group is 
most likely accurate. The major issue with this study and others is that 
pretreatment with an MAO-B inhibitor may just eliminate the conversion of MPTP 
to its active form, MPP+. The striatal DA sparing effect that is seen is simply proving 
that these inhibitors are binding to the correct target, not that MAO-B inhibitors may 
spare DA neurons in PD. These studies must be interpreted with caution.  
 
Nitric oxide synthase (NOS) and its production of nitric oxide (NO) is another large 
contributer to mitochondrial distress leading to apoptosis (Boveris, Costa, 
Cadenas, & Poderoso, 1999). A 2007 study pretreated one group of mice with 
Selegiline and studied them against the control group. The study examined the 
effect Selegiline had on intact mitochondria’s NOS activity versus the control 
group’s. They found that Selegiline decreased the amount of nitric oxide synthase 
acitivity by roughly 40%, reduced levels of hydrogen peroixde, and also protected 
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against the Ca++ induced mitochondrial depolarization leading to apoptosis 
(Czerniczyniec, Bustamante, & Lores-Arnaiz, 2007). This study confirms that the 
MAO-B inhibitor Selegiline impacts not just the oxidative stress caused by 
hydrogen peroxide created through monoamine oxidase, but also reduces 
oxidative stress caused by NOS through an unknown mechanism. No studies have 
directly examined whether Rasagiline also decreases NOS activity.  
 
C). Studies using Images of Live Cells 
Cell imaging studies are particularly important when attempting to study 
neuroprotection in PD because, in theory, they should allow researchers to directly 
see if neurons are remaining alive instead of using neuronal byproducts to detect 
cell death. Unfortunately, imaging studies in PD have been extremely difficult to 
carry out due to the uncertainty of what exactly is being measured. These studies 
in living patients are only truly detecting the receptors on neurons, to which the 
ligand is binding. The growing field of neuroplasticity tells us that neurons can 
upregulate their receptor’s in response to neuronal death, making these studies 
very unreliable for PD research.   In studies where there is confidence in what is 
being measured it is impossible to determine true neuroprotection from slightly 
different highlighted areas on a scan. The best imaging studies for PD research 
are those which allow direct viewing of individual cells, to avoid these pitfalls.  
A 2015 study examined DA neurons in embryonic rats. The researchers made sure 
the neurons contained Tyrosine Hydroxylase so that they could view, and count 
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the number of live neurons by immunohistochemically staining against TH.  The 
neurons were divided into different groups which were either exposed to normal 
human cerebrospinal fluid (CSF) or the CSF of diagnosed PD patients. The 
neurons treated with PD patient’s CSF are reduced in number compared to the 
baseline untreated model (A) after 48 hours (D), and an even more dramatic 
decrease after 96 hours (E). Interestingly, neurons treated with normal human CSF 
show a similar decrease after 48 hours (B) as the neurons treated with PD CSF. 
These neurons treated with normal human CSF however show almost a complete 
recovery after 96 hours (C).  This non-recovery indicates that the CSF of PD 
patients is causing cellular death in these neurons. This cellular death is not seen 
when treated with normal human CSF.  
 
FIGURE 19: Treatment of Embryonic Rat DA Neurons with Human PD and 
Non-PD CSF.  
Image A shows the normal untreated embryonic rat cells stained with TH 
antibodies. Image B shows the rat cells 48 hours post treatment with normal 
human CSF. Image C shows the cells 96 hours post treatment with normal human 
CSF. Image C shows a 90% recovery rate compared to baseline. Image D shows 
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cells treated with human CSF of confirm PD patients 48 hours post treatment. 
Image D and B are remarkably similar indicating that human CSF alone causes an 
initial decline in cells. Image E shows cells treated with human CSF of confirmed 
PD patients 96 hours post treatment. These cells have not only not shown the 
improvement seen in Image C, but they show a remarkable decline in cell number.  
(Kong et al., 2015).  
After establishing that human CSF from PD patients drastically reduced neuron 
numbers after 96 hours, the researchers pre-treated neurons with Selegiline 
(Figure 20). The progression from images C-E shows the impact of the CSF from 
PD patients on these rat neurons (C-D), and the benefit from Selegiline (E). In the 
96 hours post-treatment of human PD confirmed CSF (image D) there are very few 
intact neuronal bodies. Instead much of the staining is occurring outside cell 
bodies, indicating that cellular lysis is prevalent. Image E shows little neuronal 
death and is similar to image B which shows the neurons 96 hours post-treatment 
of human non-PD CSF. Pre-treating with Selegiline has a dramatic effect in 
decreasing neuronal loss. 
 
Lactate dehydrogenase (LDH) activity is known marker of tissue damage (Khan et 
al., 2013). The group of neurons treated with PD CSF showed high amounts of 
LDH activity when treated with no Selegiline or with 0.125 µM Selegiline. The 0.25 
µM and 0.5 µM doses of Selegiline reduced LDH activity in the tissue by a 
significant amount (Figure 20). This leads to the conclusion that the neurons were 
indeed showing biochemical signs of cellular damage, aside from the 
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morphological data, and Selegiline also reduced this biochemical marker (Kong et 
al., 2015). 
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FIGURE 20: Morphological and Biochemical Changes Associated with 
Selegiline Pre-Treatment. 
 Image A shows the DA neurons after adding human non-PD CSF 48 hours post-
treatment. Image B shows the neurons 96 hours post-treatment of human non-PD 
CSF. Image C shows morphological changes in the neurons 48 hours post-
treatment with human PD CSF, and Image D shows this 96 hours later. Image E 
shows the neurons pre-treated with 0.5 µM Selegiline, with added human PD CSF. 
Image F shows neurons pre-treated with 10 µM Piribedil, a DA agonist, combined 
with human PD CSF. The chart below shows the difference in LDH activity 
comparing to the control group of human CSF against the group treated with 
human PD CSF with or without the addition of varying doses of Selegiline.  
 (Kong et al., 2015) 
  
 
A 2016 paper utilized the 6-OHDA model of PD to test whether Safinamide exerted 
similar neuroprotective effects. This paper ran two studies with similar designs. In 
both studies rats were injected unilaterally with 6-OHDA, with the contralateral side 
serving as the control. In both studies the rats were treated with Safinamide which 
was administered via a subcutaneous osmotic mini-pump which began 
administering Safinamide 24 hours after its implantation. In the first study the pump 
was implanted the same day as the injection of 6-OHDA, and in the second study 
the pump was implanted a day later leading to a 48 hour delay in drug start time. 
The pump provided the researchers with a method to ensure constant drug levels, 
and in each study one group was injected with 6-OHDA and implanted with a mini-
pump that pumped distilled water as the vehicle. DA neurons were measured using 
immunohistochemical staining against TH (Sadeghian et al., 2016).  
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In the first study researchers found that rats treated with vehicle showed around a 
50% loss in DA neurons in the SNPC. Rats treated with low or high doses of 
Safinamide showed much less DA neuron loss (Figure 21) (P<0.005 and P<0.001 
respectively) (Sadeghian et al., 2016). These results at first glance seem to 
indicate that Safinamide is exerting a neuroprotective effect. The 6-OHDA treated 
lesion treated with distilled water shows a major loss in DA neurons. This could not 
be attributed to the vehicle as the contralateral non-lesioned side was also treated 
with vehicle and shows no DA loss. The Safinamide treatment clearly shows a 
sparing of these DA neurons, and shows increasing sparing with an increasing 
dose.  
 
This neuroprotection may not translate to human PD at all however. There is a 
possibility that Safinamide is interacting in some way with the 6-OHDA and not 
allowing it to kill the DA neurons. Study two is performed to ensure that the result 
is not being affected by a potential interaction between 6-OHDA and Safinamide. 
An entire 48 hour span is left between the injection of 6-OHDA and the beginning 
of Safinamide treatment, which ensures that the study is not showing any 
interaction between the interventions.  
 39 
 
 
FIGURE 21: Results of Study One Examining the Loss of DA Neurons  
(Sadeghian et al., 2016) 
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This second study with delayed administration of Safinamide shows similar results 
to study one. The researchers again show that 6-OHDA treated with vehicle kills 
around 50% of DA neurons. It is shown that treatment with Safinamide even 
starting two days later can greatly reduce the amount of neural loss. Safinamide 
treatment also lead to reduced microglial activation, signaling that there is less 
inflammation present in the area (Figure 22).  
 
FIGURE 22: Results of Delayed Safinamide Treatment on Microglial 
Activation and Dopaminergic Neural Loss.  
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(Sadeghian et al., 2016) 
 
The study states that they were only staining cell bodies which remained intact, 
not just remnants of dead cells. They accomplished this by incubating the post-
mortem neural tissue in H2O2, which would not allow for endogenous peroxidase 
activity, ensuring only whole, intact cells would be stained. This provides more 
validity to their results because of the likelihood that only live cells are being 
examined.  
 
The effect that Safinamide has on decreasing the presence of neuroinflammation 
is one that should be examined further. A likely explanation could simply be that 
Safinamide is decreasing the amount of damaged and dying DA neurons, which is 
in and of itself causing less inflammation. While this would still be a sign that 
Safinamide is neuroprotective, this microglial mechanism would require further 
examination.  
 
Ultimately these animal model and in-vitro studies provide reasonable evidence 
that MAO-B inhibitors reduce neuronal cell death. The exact mechanism for this is 
unknown, but strong evidence is provided which suggests that a reduction in 
oxidative stress could be a large piece of the puzzle. These models for PD are our 
best hope to attempt to recreate the disease in the laboratory, however they are 
no substitute for the actual parkinsonian brain.  
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CLINICAL STUDIES OF MONOAMINE OXIDASE INHIBITORS 
Clinical studies have examined two major potential benefits of MAO-B inhibitors. 
The first potential benefit examined was the potential for MAO-B inhibitors to 
provide symptomatic relief for PD patients. The second aspect of these studies 
was to see if MAO-B inhibitors could provide the same level of neuroprotection that 
researchers had seen in the aforementioned studies, now in a human population. 
  
A). Symptomatic Effects 
There have been tens of studies involving MAO-B inhibitors and their effects on 
nigrostriatal DA and oxidative stress reduction. Many of those studies convincingly 
showed that MAO-B inhibitors could serve two very needed roles in symptomatic 
PD treatment. As a monotherapy, MAO-B inhibitors have been shown to be a 
potential delayer of Levodopa onset. As an adjunctive therapy alongside L-Dopa, 
MAO-B inhibitors have shown that they lower the required dosage of L-Dopa 
needed, increase the daily on time with L-Dopa, and decrease the daily off time 
with L-Dopa treatment. MAO-B inhibitors as monotherapy and as an adjunct 
therapy have shown a decrease in reported PD motor symptoms.  
1). Selegiline  
The DATATOP (Deprenyl and Tocopherol antioxidant therapy of Parkinsonism) 
study, started in 1977 and completed in 1988, was a large scale double-blind, 
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placebo controlled study. DATATOP specifically examined whether early stage PD 
patients treated with varying combinations of Selegiline and an antioxidant, 
tocopherol, would see enough improvement in their symptoms to delay the need 
to begin Levodopa treatment. DATATOP accomplished this by randomly placing 
over 800 patients into one of four treatment groups: 1. 10 mg daily Selegiline alone 
2. 2,000 I.U. daily Tocopherol alone 3.  10 mg Selegiline plus 2,000 I.U. Tocopherol 
daily or 4. placebo. The DATATOP study also took into consideration that the need 
to start Levodopa treatment was subjective, so each investigator was allocated 
approximately the same number of subjects from each treatment group. 
 
The DATATOP study found no difference in outcome between patients treated with 
Tocopherol, and thus grouped patients into two groups: Group A, no treatment with 
Selegiline composed of groups 2 and 4, and Group B, treatment with Selegiline 
composed of groups 1 and 3. The study revealed that at the end of the study 176 
of the 401 patients in group A were placed on Levodopa whereas only 97 of the 
399 patients in group B were placed on Levodopa, a significant difference (P<10-
8). (“Effect of deprenyl on the progression of disability in early Parkinson’s disease. 
The Parkinson Study Group,” 1989). The study ultimately reveled that Selegiline 
was able to provide enough symptomatic relief that the physicians could delay the 
need to onset L-dopa by nine months(“Effect of deprenyl on the progression of 
disability in early Parkinson’s disease. The Parkinson Study Group,” 1989).  
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Selegiline also has uses as an adjunct therapy to levodopa. In Brannan and Yahr’s 
1995 study they had two groups of patients. One group taking L-dopa-Carbidopa 
and one group taking L-dopa-Carbidopa, and Selegiline. They demonstrated that 
the group using a combination of L-dopa-Carbidopa and Selegiline could take 
lower doses of L-dopa to achieve a relief in symptoms. Daily on times of L-dopa 
were also increased in the Selegiline group. The UK Parkinson’s Diseases 
Research Group did further research looking at the therapeutic effects that adjunct 
Selegiline, in combination with Levodopa, may confer. The three-year interim 
report of their study confirmed Brannan and Yahr’s results. The UK Parkinson’s 
Diseases Research Group found that Selegiline and Levodopa combined required 
a lower mean dose of Levodopa to achieve the same symptomatic relief as L-Dopa 
only (Lees, 1995).  
 
Not everything in the studies resoundingly proves that Selegiline is providing a 
symptomatic benefit. The final four-year report of Lees’ 1995 paper used Webster 
disability scores, which are similar to the motor portion of the UPDRS, to measure 
dyskinesia and motor dysfunction. This final report did not detect a statistically 
significant difference in this score between the two groups however, the L-dopa 
only arm did have slightly worse scores which can be observed in figure 23 (Lees, 
1995). Figure 23 does show that the difference in disability scores before the 
interim report were almost identical, and by the time the 3 and 4 year follow up 
occur there was much more separation. This could be reflective of the progressive 
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nature of PD, and as patients’ symptoms worsened over time they noticed more 
benefits from the combination of Selegiline and L-Dopa.  
 
FIGURE 23: Difference in Patients mean disability scores.  
(Lees, 1995).  
 
Selegiline has proven to be a symptomatic treatment for PD both as a 
monotherapy and alongside Levodopa. As a monotherapy Selegiline has shown 
that it delays the start of Levodopa treatment by providing symptomatic relief. 
Adjunct to Levodopa, Selegiline reduces symptomatic effects of PD better than just 
L-Dopa alone. Despite several studies not being able to reproduce this data there 
is support that Selegiline provides some level of symptomatic relief alongside L-
dopa, similar to many other available PD medications.  
2). Rasagiline  
The first major study involving Rasagiline was the TEMPO study, which examined 
Rasagiline as a monotreatment for PD. Subjects in the TEMPO study were in early 
stage PD, and did not yet require dopaminergic intervention. The study was 
double-blind and involved three separate patient groups. The first group was a 
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placebo control group, the second received 1 mg Rasagiline, and the third group 
received 2 mg Rasagiline. The study ran for 26 weeks. The first week was a 
“maintenance” week where all patients on active dose took 1mg Rasagiline, and 
in the second week the 2 mg group began taking their full dose. The outcome 
measure of the study was UPDRS ratings.(“A Controlled Trial of Rasagiline in Early 
Parkinson Disease,” 2002). The results of the TEMPO study suggested that 
Rasagiline is offering patients relief from their symptoms as the 1 mg dose and the 
2 mg dose show lower UPDRS scores on average by 4.20 and 3.56 points 
respectively (Figure 24).  
 
FIGURE 24: RESULTS OF TEMPO STUDY.  
(“A Controlled Trial of Rasagiline in Early Parkinson Disease,” 2002) 
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The LARGO study was a double-blind study which examined Rasagiline treatment 
as an adjunct to L-dopa. LARGO studied the ability of this combination to reduce 
off times and reduce motor fluctuations during both on and off times. This 18-week 
study compared the placebo, only taking L-dopa, to a test group, taking 1mg 
Rasagiline in combination with L-dopa. The LARGO study also used a third arm of 
the study to compare Entacapone, a COMT inhibitor, in conjunction with L-dopa 
against a placebo, however this is beyond the scope of this paper. LARGO looked 
at self-reported off times, on-time dyskinesia or lack thereof, as well as UPDRS-
motor (on-time) scores and UPDRS-ADL (off-time) scores. Rasagiline reduced the 
average daily off time by one hour and eighteen minutes. Interestingly, the placebo 
also reduced the mean off time by forty minutes; even with this demonstration of 
the placebo effect, Rasagiline’s effect is significant. Rasagiline increased the 
amount of on-time without troublesome dyskinesia’s in comparison to the placebo. 
The LARGO study also showed that Rasagiline lowered UPDRS motor scores 
during the on time, as well as during the off time (Figure 25). (Rascol et al., 2005) 
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FIGURE 25: LARGO STUDY RESULTS 
(Rascol et al., 2005) 
 
The PRESTO study is very similar to the LARGO study in its methods and 
measured outcomes. The major difference in the PRESTO study is instead of just 
one Rasagiline dose both a 1 mg and a 0.5 mg dose of Rasagiline in combination 
with L-Dopa were examined. The PRESTO study found very similar results to the 
LARGO study. The 1 mg dose of Rasagiline reduced patient’s “off-time” by 1.85 
hours and the 0.5 mg dose reduced daily mean “off-time” by 1.41 hours (Parkinson 
Study Group, 2005). The PRESTO study showed that the placebo group also 
lowered the mean “off-time” by around .91 hours. This is similar to the strong 
placebo effect seen in the LARGO study (Parkinson Study Group, 2005).  
 
The LARGO & PRESTO studies have one potential caveat: the use of concomitant 
medication. The LARGO study reports that about sixty percent of patients (130-
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141 per group) were using dopamine agonists, about thirty percent (60-70 per 
group) using Amantadine, and finally about ten percent (20-35 per group) using 
anticholinergics (Rascol et al., 2005). A similar breakdown of concomitant 
medication was observed in the PRESTO study as well. Each of these medication 
classes have shown to some degree that they may have similar effects as those 
highlighted in the LARGO & PRESTO studies. The researchers argue that since 
the placebo group in each study is also on approximately the same medications it 
is extremely unlikely the result is driven by another medication. Both PRESTO and 
LARGO however showed that their placebo group also showed benefits, which 
could be attributed to these medications. Rasagiline groups did ultimately did show 
statistically significant numbers showing they were better than the placebo groups. 
This gives validity to the study’s results; however, it is still possible that the effects 
of Rasagiline are due to a combination with one of the other medications in the 
cocktail and not completely attributable to Rasagiline.     
3). Safinamide  
Safinamide is examined in two major clinical studies both of which assess for 
Safinamide’s usefulness as an adjunct therapy to L-Dopa. These studies, like the 
PRESTO and LARGO studies, allowed for the use of a cocktail of PD medications 
to be used by the patients during the study. 
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The SETTLE study examined Safinamide’s ability to increase on time as adjunct 
therapy to L-dopa. In this study, randomized patients were either given 50 mg 
Safinamide or placebo. If the 50 mg dose was tolerated well after fourteen days, 
then the 50 mg dose was increased to 100 mg. This left the study with two groups 
after the 24 weeks of treatment Safinamide (either on 50 or 100 mg) or Placebo 
treated. Ninety percent of the patients in the Safinamide group ended up being 
treated with the 100mg dose.  
At week 24, the mean increase in total daily on time without troublesome 
dyskinesia (primary efficacy outcome) was +1.42 hours in the Safinamide group 
and +0.57 hours in the placebo group (least-squares [LS] mean difference, 0.96 
hour; 95% CI, 0.56-1.37 hours; P < .001). In addition to the primary outcome the 
SETTLE study also showed that Safinamide reduced mean daily off time in 
patients by 1.54 hours versus the placebo group which lowered mean daily off time 
for patients by 0.54 hours (Schapira et al., 2017). The motor section of the UPDRS 
(UPDRS III) was improved drastically when compared to placebo (Figure 26) 
(Schapira et al., 2017) 
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FIGURE 26: SETTLE Study results Primary Outcome and Key Secondary 
Outcomes. 
(Schapira et al., 2017).  
 
The SETTLE study, despite showing strong significance that Safinamide increases 
mean daily on time with L-dopa, is only looking at data from 24 weeks of 
intervention. Borgohain et.al. examined the effect Safinamide treatment had as an 
adjunct to Levodopa after a total 24-months. The primary end-point of their study 
was the total on time without any troublesome dyskinesia. Other end points of the 
study included change in daily on-time without troublesome dyskinesia, depressive 
symptoms, or changes in quality of life measures. This study began as only a 6-
month study like the SETTLE study, but then was extended another 18-months to 
yield needed long term data. It is worth noting that 50 of the 594 enrolled dropped 
out of the study after the first sixth months, and that again 60% of the enrolled 
patients were also taking another drug for PD treatment other than L-dopa. 
  
The primary end-point of the study was met by both the 50 and 100mg dose of 
Safinamide which showed a 31% and 27% decrease, respectively, in UPDRS 
motor scores versus placebo during on-time. (Borgohain et al., 2014). In addition 
to this primary end-point both Safinamide doses showed an increase in total daily 
on-time when compared to placebo (Figure 27).  
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 FIGURE 27: Daily On-Times with Safinamide 50 and 100mg dose vs. Placebo 
(Borgohain et al., 2014).  
 
The mean dose of L-dopa increased for the placebo group and the 50 mg 
Safinamide group, but decreased for the 100 mg Safinamide group (Borgohain et 
al., 2014). The study went on to examine how the patients mean UPDRS motor 
scores changed with Safinamide treatment versus placebo. There was no 
statistical change in motor UPDRS scores for Safinamide treated patients versus 
placebo treated patients (Figure 28). However, 74% of the patients had UPDRS 
motor scores less than 4 which does not allow them much room for improvement. 
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When only examining patients whose motor UPDRS scores are above 4, the study 
shows that the 100mg dose was significant in reducing the mean UPDRS motor 
scores.  
 
FIGURE 28: Mean UPDRS Part III Scores 50 or 100mg Safinamide vs. 
Placebo.  
(Borgohain et al., 2014). 
 
 
The SETTLE study and Borgohain’s 24 month study provide convincing data that 
Safinamide alone, or in conjunction with another concurrent PD medication, 
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dramatically improved the performance of Levodopa.  Safinamide is shown to 
reduce daily off time, increase daily on time, and lower the motor symptoms of 
patients during on time as rated by the UPDRS section III. These results add 
Safinamide to the list of MAO-B inhibitors who provide marked benefits as an 
adjunct therapy to Levodopa.   
 B). Potential Neuroprotective Effects 
Clinical studies are extremely limited in how they can show potential 
neuroprotection by MAO-B inhibitors. If MAO-B inhibitors do provide a 
neuroprotective effect the clinical manifestation of this would be a decrease in 
symptoms, a lower dose of L-Dopa required, or the delay for the need of L-Dopa 
onset. These same outcomes however are also measures of symptomatic 
benefits, reflectively of increased nigrostriatal DA levels. Thus, the challenge of 
discerning between symptomatic benefits or a true disease modifying effect 
presents itself.  
 1). Selegiline  
Selegiline, as the pioneer of MAO-B inhibitors, was the first to be implemented in 
clinical studies. The results of the DATATOP study suggest that Selegiline is 
providing alleviation to patients’ symptoms. One mechanism that Selegiline may 
be doing that is by delaying the progression of PD, and potentially altering the 
course of the disease. Support for this could be seen from the DATATOP study 
since the Selegiline group delayed the onset of L-Dopa by a whole 9 months 
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compared to the non-Selegiline group. Neuroprotection, although alluded to, 
cannot be definitively concluded from the DATATOP study.  
More direct support that Selegiline could be a neuroprotectant comes from Lees 
and colleagues 1995 study. They showed that over the course of 4 years of 
treatment the daily amount of L-dopa required to provide symptomatic relief did not 
increase in the Selegiline group. In the group treated only with L-dopa, the daily 
amount of L-dopa increased by 66% over the course of the four-year study.  
 
The preceding results provide interesting data which allowed clinicians to 
speculate over Selegiline’s potential to modify the course of PD. This potential 
neuroprotective effect by Selegiline was severely doubted after the UK Parkinson’s 
Disease Research Group’s report found no difference in the mean length of time 
to develop dyskinesia and motor oscillations between the Levodopa only and 
Selegiline and Levodopa group (“Comparisons of therapeutic effects of levodopa, 
levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson’s 
disease,” 1993).  
 
Brannan and Yahr’s study also showed that each treatment group had no 
difference in the patients’ severity of disease, motor sub scores for tremor, or in 
reported dyskinesia (Brannan & Yahr, 1995). These studies show that long term 
Selegiline treatment failed to show a difference in motor symptoms and length of 
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time between patients’ motor symptoms. This result casts reasonable doubt that 
Selegiline is able provide a neuroprotective effect.  
2). Rasagiline 
The TEMPO study runs into the same issue that the DATATOP study had run into, 
the researchers are not definitively proving a disease modifying/neuroprotective 
effect. Like DATATOP, the TEMPO study provides interesting points which could 
in some way allude to neuroprotection. TEMPO ultimately asks more questions 
than it solves however. The ADAGIO study was the major study done which 
attempted to prove not just symptomatic benefit, but also a definitive 
neuroprotective effect.   
 
The ADAGIO study, run by Olanow and colleagues, was the most impactful study 
involving MAO-B inhibitors. The ADAGIO study split 1176 patients into two groups. 
The first group was given Rasagiline on day one in either a 1 mg or 2 mg dose. 
The second group received placebo the first 36 weeks, and after that received 1 
mg or 2 mg Rasagiline. To determine positive results each group had to meet three 
criteria using the UPDRS:  
1). Superiority to placebo on the UPDRS between weeks 12 and 36.  
2). Superiority to the delayed start treatment in the change in the score 
between baseline and week 72.  
3). Finally, they must demonstrate noninferiority to delayed start treatment 
in the rate of change in the score between weeks 48-72. 
 57 
 
The first criterion was designed to examine whether there is a difference in the rate 
of progression in each Rasagiline group versus the placebo. While this is true the 
UPDRS is examining parkinsonian like symptoms so the first criterion can only 
definitively show that Rasagiline is more effective at decreasing the symptoms of 
PD. The second criterion examines the overall change in UPDRS scores between 
the early start group and the delayed start group. This criterion showed whether 
benefits experienced by the early start group were still greater even when the 
delayed start group began receiving Rasagiline. Per Olanow, a positive result in 
the second criteria would also show a disease modifying effect which is less 
arguable than with the first criteria. The third criterion examines weeks 48-72 and 
was designed to show if the early group is declining at the same rate as the patients 
in the delayed group. This is important because if the delayed group is not showing 
worsening, meaning UPDRS scores not increasing as rapidly as the early group, 
patients this would suggest that the benefit Rasagiline provided was a “prolonged 
and cumulative effect on symptoms”. Conversely if both groups of patients are 
declining at the same rate when the delayed start group has been on the drug for 
36 weeks fewer, this would suggest a disease modifying effect.  
 
The delay group is really what allows ADAGIO to examine the potential 
neuroprotective effect of Rasagiline. An identical group starting 36 weeks after the 
first group allows a comparison to be made with not only a placebo control, but 
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also allows the opportunity to quantitatively see more lasting, permanent benefits 
in the early start group compared to the delayed group. 
 
 
Figure 29: ADIGO Study results schematic. 
The Yellow dashed line indicates the placebo time and the Light Blue line indicates 
Rasagiline. The Green arrow therefore shows the first criteria. This shows that the 
early start group did in fact have a greater mean improvement in UPDRS scores 
over the placebo. The Red arrow shows that the early start was more effective 
than the delayed start group, or the second criteria. Finally, the Dark Blue arrow 
shows that the early treatment group did not have a worse rate of change in 
UPDRS scores compared to the delayed start group.  
(Olanow et al., 2009)  
 
  
The 1 mg dose of Rasagiline met all three of the study criteria, suggesting an ability 
to modify the course of PD. The 2 mg dose of Rasagiline did not meet all three of 
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the criteria in the study. The 2 mg dose of Rasagiline met criteria one and three, 
however did not meet criterion 2.  This result indicates that the 2 mg dose of 
Rasagiline could very possibly have disease modifying neuroprotective effects, or 
it could indicate that the result of the 1 mg treatment group is showing a false 
positive result.  
 
The in-depth analysis then for the 2 mg groups is as follows. Early 2 mg treatment 
group was better than placebo for 36 weeks, which gave positive result to criteria 
one. Early 2 mg treatment group and delayed 2 mg treatment group showed that 
they declined in efficacy at the same rate from week 48-72, positive result to criteria 
three. It is easy to assume that the failure to show that the early 2 mg treatment 
group did better overall (baseline to week 72) would have been due to the delayed 
2 mg treatment group’s response to Rasagiline between week 36-48.  Figure 30 
shows us otherwise however. The main difference in the two dosage groups 
occurs from baseline to week 12 in the early treatment group. The early treatment 
1 mg group shows a mean improvement in UPDRS scores of roughly 1.8 points, 
and the delayed start group on placebo shows a .4-point worsening in UPDRS 
scores. Conversely, we see in the early 2 mg treatment group there is only a .9-
point improvement in UPDRS scores and the delayed start placebo group shows 
no worsening in there UPDRS scores.  
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FIGURE 30: Analysis of 1mg versus 2mg Rasagiline.  
(Olanow et al., 2009). 
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DISCUSSION 
There is little debate, if any, that MAO-B inhibitors provide symptomatic benefits 
alongside L-Dopa. The presented studies and several others have consistently 
reaffirmed that they increase patients’ quality of life by reducing PD symptoms, 
reducing daily off time, and increasing daily on-time. While this is important for 
clinicians treating PD, the true importance of MAO-B inhibitors is their potential as 
disease modifying agents. There is a glaring disconnect between the basic science 
and the clinical trials, and this is where MAO-B research has run into an impasse. 
The basic science studies are designed very well using our best current models of 
PD, and use a great deal of in vivo work in live cells. The convincing results that 
are observed in these studies translate very little to the clinical realm, where even 
the studies with the best designs to show neuroprotection, namely the ADAGIO 
study, show only modest neuroprotective effects, if any.  
 
The ADAGIO study’s failure to present readers a clear cut neuroprotective effect 
was due to the fact the placebo group in the 2 mg study did not have a worsening 
UPDRS score in the first 12 weeks, combined with the relatively weaker UPDRS 
score improvement in the 2 mg group. This difference in data from baseline to 
week 12 in the 2 mg group is very different from what was expected by Olanow. 
The picture that the ADAGIO study paints is now very cloudy for clinicians. Is the 
1 mg dose a false positive result? Is the 2 mg dose a false negative result? In the 
TEMPO study and the PRESTO study the 1 mg was more effective than either the 
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2 mg or 0.5 mg dose respectively.  Does this mean the results could be accurate 
and in fact only the 1 mg dose is truly neuroprotective, implying a J-shaped curve 
for Rasagiline?  
 
A post-hoc analysis showed that for both the 1 mg and 2 mg treatment groups the 
only subset of patients who showed statistically significant improvement in all three 
criteria were those whose UPDRS scores at baseline were in the top quartile, and 
thus had the most severe PD symptoms. The patients whose UPDRS scores were 
in the bottoms three quartiles showed no significant improvement in criteria one or 
two for either the 1 mg or 2 mg dose; however, these patients did meet criteria 
three for both doses which the researcher identified as a major determinant of 
disease modification1. These results suggest that a disease modifying presence is 
seen only in patients who have advanced PD. This leads clinicians to question why 
Rasagiline would only be able to modify the course of the disease in its later, more 
symptomatic stages. It is possible that patients not in the top quartile exhibit a floor 
effect, and that it is just impossible to statistically show the benefits with the 
UPDRS until patients have more advanced PD. This could help explain why only 
DA starved, advanced PD patients meet all the criteria in both dosage groups.  It 
is also possible that Olanow’s delayed start model is still only capable of showing 
symptomatic effects and not neuroprotection with the UPDRS as the primary tool 
                                                        
1 These results can be seen in Appendix 3. 
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utilized. Olanow and his colleagues however have proposed that the 2 mg dose 
failed to show a positive response because the symptomatic benefit was large 
enough to overshadow the disease modifying effect (Olanow et al., 2009).  
 
Though Olanow’s rationale seems plausible Ahlskog and Uitti highlight three major 
issues with the ADAGIO study and PD studies in general. The first issue that they 
discuss is that the measured changes in the trials are very small and can be easily 
overshadowed by other factors. To highlight how small the measured changes are 
Ahlskog and Uitti point out that in each Rasagiline study the measured difference 
between the two groups was about two units on the UPDRS. The second issue 
that Ahlskog and Uitti bring up is the “double” blinding of these delayed studies. 
They note that these studies are only double blind during the first half of the study 
while the second half becomes open label. This can introduce many biases. The 
counterpoint to this is that Olanow was not examining the effect of Rasagiline 
against placebo, but rather the delayed start group over the early start. Their third 
point is also centered around a bias. The UPDRS scoring can also be considered 
bias to a degree. Take for example the following subtle scoring distinction where 
a 1= “rare freezing when walking: may start hesitation” and a 2= “occasional 
freezing when walking”. When an essentially open label study is using highly 
subjective ratings, and a 1% change in scores is statistically significant, there is 
reasonable doubt in the validity of the findings.  
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Considering the basic research and, at the very least, the intriguing data obtained 
from the ADAGIO study, there is still a possibility that MAO-B inhibitors may 
provide some sort of neuroprotection. With the current techniques available to 
researchers to study PD, there is no way to prove neuroprotection beyond a 
reasonable doubt. The ADAGIO study uses a very logical study design in the 
delayed start model, but there is still reasonable doubt due to the subjectivity of 
the UPDRS. Even moving to the modified MRS-UPDRS and using a similar study 
design to ADIGO would not be enough to prove convincing results, due the small 
difference in scoring (~1%) combined with the subjectivity of the questionnaire.  
 
Better ways to study the progression of PD are needed to have an accurate picture 
of neuroprotection in PD. The Parkinson’s Progression Markers Initiative (PPMI) 
lead by the Michael J. Fox Foundation is a large scale research project looking for 
just this. Markers in CSF, genetic markers, and advances in imaging are all being 
called for to help fill in the many blanks across PD research.  The true breakthrough 
of Parkinson’s research isn’t MAO-B inhibitors, but rather in the discovery of tools 
that can detect their possibilities.  
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APPENDIX 1 
Information taken from The Clinicians and Nurses Guide to Parkinson’s.  
(“The Clinicians’ and Nurses’ Guide to Parkinson’s Disease,” n.d.) 
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APPENDIX 2 
Information adapted from The Pharmacy Times. “Treating Parkinson’s Disease: 
The Pharmacist’s Role” and educatehealth.ca.  
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Source: (Wick, Jeanette, n.d.).  
 
 
Source: (“eDucate |  Parkinson’s disease,” n.d.).  
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APPENDIX 3 
 
Source:(Olanow et al., 2009) 
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Source: (Olanow et al., 2009)  
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